LTZ 232
Alternative Names: LTZ-232Latest Information Update: 01 Aug 2024
At a glance
- Originator LTZ Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Macrophage stimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours